A multinational pharmaceutical company is looking for novel technologies or methodologies that allow antibody-drug conjugation. Specifically, our client is interested in novel linker conjugation technologies for mAB conjugation with conventional small molecule drugs. Approaches should use novel methods that provide improved serum stability and physicochemical properties compared to conventional conjugation methods.
Approaches of Interest
- Novel approaches for cysteine residue conjugation in the hinge region of mAb that improve on stability/physicochemical...